Coti Iuliana, Haberl Thomas, Scherzer Sabine, Werner Paul, Shabanian Shiva, Kocher Alfred, Laufer Guenther, Andreas Martin
Department of Surgery, Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
Ann Cardiothorac Surg. 2020 Jul;9(4):314-321. doi: 10.21037/acs.2020.04.01.
The Edwards Intuity Valve System is a bioprosthesis with a balloon-expandable stent frame which enables rapid-deployment (RD). We aimed to analyze our single-center long-term experience with a follow-up until 9 years after aortic valve replacement (AVR) with this bioprosthesis.
Between May 2010 and May 2019, 700 consecutive patients with severe aortic stenosis or combined aortic valve disease, implanted with a RD valve at our institution, were included in a prospective database. Median follow-up was 19 months and the total accumulated follow-up was 2,140 patient-years. Pre-operative characteristics, operative parameters, survival rates, valve-related adverse events and valve hemodynamics were assessed.
Mean age was 74±8 years, 45% female. Concomitant procedures were performed in 339 (48.4%) patients. In case of isolated AVR (361/700), a minimally invasive surgical (MIS) approach was conducted in 283 patients (78.4%). Cardio-pulmonary bypass (CPB) and cross-clamp times for isolated AVR were 107.7±28.2 and 73.8±21.3 minutes for MIS approaches and 92.8±28.8 and 57.5±20.6 minutes for full sternotomy (P<0.001), respectively. Mean gradients at discharge, 1, 3 and 5 years were 13±5, 11±4, 12±5 and 13±8 mmHg. New early pacemaker implantation was required in 8.9% of patients. Re-intervention or re-operation with valve explantation for structural degeneration, non-structural dysfunction or endocarditis, occurred in 21 cases (3%). Thirty-day mortality was 0.7% (5/700) and overall survival at 1, 3 and 5 years was 98%, 91% and 76%.
We report excellent long-term results in this updated single center experience for RD aortic valves regarding durability, safety and hemodynamic performance.
爱德华兹Intuity瓣膜系统是一种带有球囊可扩张支架框架的生物假体,可实现快速部署(RD)。我们旨在分析在本单中心使用该生物假体进行主动脉瓣置换术(AVR)后长达9年随访的长期经验。
2010年5月至2019年5月期间,在我们机构连续700例患有严重主动脉瓣狭窄或合并主动脉瓣疾病并植入RD瓣膜的患者被纳入前瞻性数据库。中位随访时间为19个月,累积随访时间为2140患者年。评估术前特征、手术参数、生存率、瓣膜相关不良事件和瓣膜血流动力学。
平均年龄为74±8岁,女性占45%。339例(48.4%)患者进行了同期手术。在单纯AVR(361/700)的情况下,283例患者(78.4%)采用了微创外科(MIS)方法。单纯AVR的体外循环(CPB)和主动脉阻断时间,MIS方法分别为107.7±28.2分钟和73.8±21.3分钟,全胸骨切开术分别为92.8±28.8分钟和57.5±20.6分钟(P<0.001)。出院时、1年、3年和5年的平均压差分别为13±5、11±4、12±5和13±8 mmHg。8.9%的患者需要早期植入新的起搏器。因结构退变、非结构功能障碍或心内膜炎进行再次干预或瓣膜置换再次手术的有21例(3%)。30天死亡率为0.7%(5/700),1年、3年和5年的总生存率分别为98%、91%和76%。
我们在这份关于RD主动脉瓣的单中心最新经验报告中,在耐久性、安全性和血流动力学性能方面取得了出色的长期结果。